Table 5.
MiRNAs in tumor specimens and plasma/serum samples reported to predict therapeutic response in colorectal cancer patients
| miRNA | Treatment regimen | Detection method | Expression that suggests inadequate response | Patient number | Ref. |
| Tumor specimens | |||||
| Let-7 | Irinotecan, cetuximab | qRT-PCR | Low | 59 | [102] |
| miR-7 | Cetuximab | qRT-PCR | Low | 105 | [97] |
| miR-21 | 5-FU | qRT-PCR | High | 84 | [90] |
| miR-21 | 5-FU | qRT-PCR | High | 67 | [89] |
| miR-21-5p | 5-FU + radiation | Microarray | Low | 27 | [222] |
| miR-31-3p | Anti-EGFR | Microarray, qRT-PCR | High | 33 | [98] |
| miR-31-5p | Anti-EGFR | qRT-PCR | High | 102 | [100] |
| miR-126 | Capecitabine, oxaliplatin | qRT-PCR, ISH | Low | 89 | [104] |
| miR-143 | Capecitabine, oxaliplatin, anti-EGFR | Microarray, qRT-PCR | High | 34 | [103] |
| miR-146b-3p | Cetuximab | qRT-PCR | High | 25 | [223] |
| miR-148a | 5-FU | qRT-PCR, ISH | Low | 273 | [92] |
| miR-150 | 5-FU | qRT-PCR, ISH | Low | 239 | [91] |
| miR-181a | Anti-EGFR | qRT-PCR | Low | 80 | [99] |
| miR-200 family | Fluoropyrimidine | qRT-PCR | Low | 127 | [103] |
| miR-200b | Capecitabine, oxaliplatin, anti-EGFR | Microarray, qRT-PCR | Low | 34 | [103] |
| miR-320e | 5-FU, oxaliplatin | Microarray, qRT-PCR | High | 100 | [93] |
| miR-455-5p | Capecitabine, oxaliplatin, bevacizumab | qRT-PCR, ISH | High | 212 | [224] |
| miR-486-5p | Cetuximab | qRT-PCR | High | 25 | [223] |
| miR-519c | 5-FU, irinotecan | qRT-PCR | Low | 26 | [153] |
| miR-592 | Anti-EGFR | Microarray | Low | 33 | [98] |
| miR-625-3p | Capecitabine, oxaliplatin | Microarray, qRT-PCR | High | 94 | [94] |
| miR-664-3p | Capecitabine, oxaliplatin, bevacizumab | qRT-PCR, ISH | Low | 212 | [224] |
| Let-7c, miR-99a, miR-125b | Anti-EGFR | Microarray, qRT-PCR | Low | 74 | [101] |
| miR-1274b, miR-720 | Capecitabine, oxaliplatin, radiation | Microarray, qRT-PCR | High | 38 | [96] |
| miR-107, miR-99a-3p | Fluoropyrimidine | Microarray, qRT-PCR | Low | 39 | [225] |
| miR-215, miR-190b, miR-29b-2 | 5-FU, radiotherapy | Microarray, qRT-PCR | High | 20 | [95] |
| Let-7e, miR-196, miR-450a, miR-450b-5p, miR-99a | 5-FU, radiotherapy | Microarray, qRT-PCR | Low | 20 | [95] |
| miR-17-3p, miR-193b-5p, miR-204-5p, miR-501-5p, miR-545-3p, miR-592, miR-644-3p, miR-15a-5p, miR-196b-5p, miR-552 | First-line capecitabine and oxaliplatin with or without bevacizumab | qRT-PCR, ISH | Low | 212 (screening); 121 (validation) | [224] |
| miR-1183, miR-622. miR-765, miR-1471, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-483-5p, miR-671-5p, miR-1909 | Capectabine, oxaliplatin, radiation | Microarray, qRT-PCR | Low | 38 | [96] |
| Blood | |||||
| miR-19a | FOLFOXa | Microarray, qRT-PCR | High | 72 | [226] |
| miR-126 | Bevacizumab | High | [104] | ||
| miR-143 | Oxaliplatin | qRT-PCR | Low | 62 | [227] |
| miR-155 | Leucovorin, cetuximab, 5-FU | qRT-PCR | High | 15 | [107] |
| miR-345 | Cetuximab, irinotecan | Microarray, qRT-PCR | High | 138 | [108] |
| miR-1914* | Capecitabine + oxaliplatin | qRT-PCR | Low | 49 | [228] |
| miR-106a, miR-130b, miR-484 | 5-FU, oxaliplatin | qRT-PCR | High | 150 | [105] |
| miR-20a, miR-130, miR-145, miR-216, miR-372 | FOLFOX | Microarray, qRT-PCR | High | 40 | [106] |
FOLFOX: 5-FU + oxaliplatin + leucovorin; 5-FU: 5-fluorouracil; ISH: In situ hybridization; Anti-EGFR: Anti-EGFR targeted monoclonal antibody therapy; EGFR: Epidermal growth factor receptor.